Table 1 Demographic, clinical and biological characteristics of patients enrolled in the first study
From: Local hyperhemia to heating is impaired in secondary Raynaud's phenomenon
Healthy controls (n = 20) | Primary RP (n = 20) | SSc (n = 20) | |
|---|---|---|---|
Age (years) | 47 (37–58) | 46 (37–59) | 50 (33–61) |
Female | 18 (90%) | 18 (90%) | 18 (90%) |
Body mass index (kg/m2) | 22 (20–29) | 20 (18–23) | 23 (20–26) |
Raynaud's phenomenon | 0 | 20 (100%) | 20 (100%) |
Median Raynaud's disease duration (years) | 0 | 18 (6–43) | 8 (3–22) |
Raynaud's phenomenon: median number of fingers involved | 0 | 8 (6–10) | 10 (8–10) |
Raynaud's phenomenon: thumb involved | 0 | 7 (35%) | 18 (90%) |
Raynaud's phenomenon: feet involved | 0 | 8 (40%) | 16 (80%) |
Median disease duration (years) | NA | NA | 5 (0,5–16) |
Digital pitting scars | 0 | 0 | 8 (40%) |
Sclerodactyly | 0 | 0 | 20 (100%) |
Median Rodnan modified skin score | 0 | 0 | 6 (2–29)a |
dcSSc/lcSSc | 0/0 | 0/0 | 6/14 |
Pulmonary fibrosis | 0 | 0 | 7 (35%) |
Esophageal dysmotility | 0 | 0 | 13 (65%) |
Median creatinine clearance (ml/min) | 81.7 (66–119) | 74.9 (68–97) | 87.9 (79–139) |
Microalbuminuria (mg/l) | 11 (11–17.6) | 11 (11–20.8) | 11 (11–17.7) |
Median cardiac rate (beat/min) | 62 (49–77) | 69 (52–92) | 65 (57–78) |
Median systolic/diastolic blood pressure (mm Hg) | 111 (99–133)/ 66 (54–78) | 107 (91–122)/ 62 (52–79) | 106 (89–141)/ 67 (54–85) |
Median oxygen saturation (%) | 99 (97–100) | 100 (97–100) | 100 (96–100) |
Autoantibodies | |||
Anti-centromere | 0 | 0 | 8 (40%) |
Anti-topoisomerase I | 0 | 0 | 5 (25%) |
Median plasma LDL cholesterol (g/l) | 1.04 (0.7–1.4) | 1.04 (0.6–1.4) | 0.9 (0.6–1.2) |
Median plasma triglycerides (g/l) | 0.7 (0.3–1) | 0.5 (0.4–0.9) | 0.7 (0.3–0.9) |
Median plasma glycemia (mmol/l) | 4.7 (3.6–5.3) | 4.6 (4–5.7) | 4.6 (4.3–5.2) |